UPDATE: Morgan Stanley Initiates Optimer Pharmaceuticals at Underweight on Risk/Reward

Morgan Stanley initiated coverage on Optimer Pharmaceuticals

with an Underweight rating and a $11 price target. Morgan Stanley noted, "Optimer's growth driver is Dificid, approved for treatment of C. diff. Dificid is a best in disease therapy, but reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit our sales expectations (2018 WW revenue ~$285mn). We see OPTR's risk reward as less attractive than others in our coverage universe." Optimer Pharmaceuticals closed at $12.82 on Wednesday.